NO20031238L - Xantin-fosfodiesterase V-inhibitorer - Google Patents

Xantin-fosfodiesterase V-inhibitorer

Info

Publication number: NO20031238L
Authority: NO; Norway
Prior art keywords: inhibitors; xanthine phosphodiesterase; phosphodiesterase; xanthine
Prior art date: 2000-09-19

Application number

NO20031238A

Other languages

English (en)

Other versions

NO20031238D0 (no

NO328753B1 (no

Inventor

Samuel Chackalamannil

Yuguang Wang

Craig D Boyle

Andrew W Stamford

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-19

Filing date

2003-03-18

Publication date

2003-05-14

2003-03-18 Application filed by Schering Corp filed Critical Schering Corp

2003-03-18 Publication of NO20031238D0 publication Critical patent/NO20031238D0/no

2003-05-14 Publication of NO20031238L publication Critical patent/NO20031238L/no

2010-05-03 Publication of NO328753B1 publication Critical patent/NO328753B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20031238A 2000-09-19 2003-03-18 Xantin-fosfodiesterase V-inhibitorer NO328753B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23356700P	2000-09-19	2000-09-19
PCT/US2001/028983 WO2002024698A1 (en)	2000-09-19	2001-09-17	Xanthine phosphodiesterase v inhibitors

Publications (3)

Publication Number	Publication Date
NO20031238D0 NO20031238D0 (no)	2003-03-18
NO20031238L true NO20031238L (no)	2003-05-14
NO328753B1 NO328753B1 (no)	2010-05-03

Family

ID=22877764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20031238A NO328753B1 (no)	2000-09-19	2003-03-18	Xantin-fosfodiesterase V-inhibitorer

Country Status (29)

Country	Link
US (6)	US6821978B2 (no)
EP (1)	EP1319003B1 (no)
JP (2)	JP4015547B2 (no)
KR (1)	KR100610417B1 (no)
CN (1)	CN1252071C (no)
AR (1)	AR035199A1 (no)
AT (1)	ATE433451T1 (no)
AU (2)	AU2001291022B2 (no)
BR (1)	BR0113953A (no)
CA (1)	CA2421910C (no)
CY (1)	CY1109329T1 (no)
DE (1)	DE60138955D1 (no)
DK (1)	DK1319003T3 (no)
EC (1)	ECSP034519A (no)
ES (1)	ES2326956T3 (no)
HU (1)	HUP0303016A3 (no)
IL (1)	IL154839A0 (no)
MX (1)	MXPA03002361A (no)
NO (1)	NO328753B1 (no)
NZ (1)	NZ524433A (no)
PE (1)	PE20020469A1 (no)
PL (1)	PL205188B1 (no)
PT (1)	PT1319003E (no)
RU (1)	RU2302420C9 (no)
SI (1)	SI1319003T1 (no)
SK (1)	SK3192003A3 (no)
TW (1)	TWI241301B (no)
WO (1)	WO2002024698A1 (no)
ZA (1)	ZA200301863B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
SK286975B6 (sk) *	2001-02-24	2009-08-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
DK1243263T3 (da) *	2001-03-21	2003-03-17	Sanol Arznei Schwarz Gmbh	Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
DE60225556D1 (de) *	2001-07-03	2008-04-24	Novo Nordisk As	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1463727A2 (en) *	2001-09-19	2004-10-06	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
JP2005509038A (ja) *	2001-11-09	2005-04-07	シェーリング　コーポレイション	多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
US20050107394A1 (en) *	2001-12-17	2005-05-19	Ardeschir Ghofrani	Novel use of selective pde5 inhibitors
US20030181461A1 (en) *	2002-01-25	2003-09-25	Lautt Wilfred Wayne	Use of phosphodiesterase antagonists to treat insulin resistance
WO2003101991A1 (en)	2002-05-31	2003-12-11	Schering Corporation	Xanthine phosphodiesterase v inhibitor polymorphs
MXPA04011862A (es) *	2002-05-31	2005-03-31	Schering Corp	Procedimiento para preparar inhibidores xantina de la fosfodiesterasa v, y precursores de los mismos.
SI1509525T1 (sl)	2002-05-31	2006-12-31	Schering Corp	Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
JP4491344B2 (ja) *	2002-06-17	2010-06-30	グラクソグループリミテッド	肝ｘ受容体アゴニストとしてのプリン誘導体
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en)	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) *	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
JP2007500714A (ja) *	2003-07-31	2007-01-18	シェーリング　コーポレイション	勃起不全を処置するのに有用なキサンチンホスホジエステラーゼ５インヒビターの代謝物およびそれらの誘導体
EP1659123A1 (en) *	2003-08-29	2006-05-24	Dainippon Sumitomo Pharma Co., Ltd.	Bicyclic pyrazole derivative
BRPI0416202A (pt) *	2003-11-21	2006-12-26	Schering Corp	formulações inibidoras de fosfodiesterase v
DE10355304A1 (de) *	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1689378B1 (en) *	2003-12-02	2009-04-15	Schwarz Pharma Ag	Novel use of peptide compounds for treating central neuropathic pain
BRPI0507604A (pt)	2004-02-14	2007-07-03	Smithkline Beecham Corp	medicamentos com atividade de receptor hm74a
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) *	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en)	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
EP1604655A1 (en) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) *	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005307861B2 (en) *	2004-11-18	2009-11-12	Schering Corporation	Methods of using PDE V inhibitors for the treatment of congestive heart failure
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
NZ561746A (en)	2005-04-19	2011-09-30	Nycomed Gmbh	Roflumilast for the treatment of pulmonary hypertension
MX2008000087A (es) *	2005-06-23	2008-03-18	Schering Corp	Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
DE102005035891A1 (de) *	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1912991B1 (en) *	2005-08-10	2010-11-10	GlaxoSmithKline LLC	Xanthine derivatives as selective hm74a agonists
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
WO2007070426A2 (en) *	2005-12-09	2007-06-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
KR101541791B1 (ko) *	2006-05-04	2015-08-04	베링거 인겔하임 인터내셔날 게엠베하	다형태
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
EP2992891B1 (en)	2006-06-15	2020-08-05	UCB Pharma GmbH	Pharmaceutical composition comprising brivaracetam and lacosamide with synergistic anticonvulsant effect
EP2057160A1 (en) *	2006-08-08	2009-05-13	Boehringer Ingelheim International GmbH	Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
WO2008125388A1 (en) *	2007-04-17	2008-10-23	Ratiopharm Gmbh	Pharmaceutical compositions comprising irbesartan
RU2344137C1 (ru) *	2007-07-18	2009-01-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА)	Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
AU2008290582B2 (en) *	2007-08-17	2014-08-14	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
PE20140960A1 (es) *	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20110190322A1 (en) *	2008-08-14	2011-08-04	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko)	2008-12-23	2011-09-21	베링거 인겔하임 인터내셔날 게엠베하	유기 화합물의 염 형태
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es)	2010-05-05	2023-03-03	Boehringer Ingelheim Int	Combiterapia
MX2012014247A (es)	2010-06-24	2013-01-18	Boehringer Ingelheim Int	Terapia para la diabetes.
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
ES2934843T3 (es)	2011-07-15	2023-02-27	Boehringer Ingelheim Int	Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
CN112955967A (zh) *	2018-06-14	2021-06-11	阿斯利康(英国)有限公司	用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法
CN110613717A (zh) *	2019-05-17	2019-12-27	中国医学科学院医药生物技术研究所	一种降低血脂的药物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1938016A1 (de)	1969-07-23	1971-01-28	Fischer Ohg Arzneimittelwerk	Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten
FR2116302A1 (en)	1970-12-07	1972-07-13	Brun Lab Sa Le	8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
EP0258191B1 (en)	1986-08-28	1992-05-27	Sandoz Ag	Xanthine derivatives
IT1217190B (it)	1988-04-22	1990-03-14	Recordati Chem Pharm	Composti utili per il trattamento e diagnosi di disfunzioni frettili
US5321029A (en)	1988-11-14	1994-06-14	Beecham-Wuelfing Gmbh & Co.K.G.	Xanthines
GB8906792D0 (en)	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
FR2654935B1 (fr)	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
IL98559A0 (en)	1990-06-21	1992-07-15	Schering Corp	Polycyclic guanine derivatives
GB9020921D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
GB9020959D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
DE69132291T2 (de)	1990-12-21	2000-12-14	Beecham Group P.L.C., Brentford	Xanthinderivate
US5256766A (en)	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en)	1991-02-19	1997-11-18	Cor Therapeutics, Inc.	Recombinant thrombin receptor and related pharmaceuticals
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9210839D0 (en)	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds
TW252044B (no) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
GB9226532D0 (en)	1992-12-21	1993-02-17	Smithkline Beecham Plc	Compounds
IL108754A0 (en)	1993-02-26	1994-06-24	Schering Corp	2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US6143746A (en)	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
KR100430059B1 (ko)	1995-04-10	2004-09-24	후지사와 야꾸힝 고교 가부시키가이샤	cGMP-PDE억제제로서의인돌유도체
US5731339A (en)	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
AU722514B2 (en)	1995-12-28	2000-08-03	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
ES2175404T3 (es)	1996-05-10	2002-11-16	Icos Corp	Derivados de carbolina.
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
NZ330292A (en)	1996-08-30	2000-01-28	Kyowa Hakko Kogyo Company Ltd	Imidazoquinazoline derivatives
WO1998015530A1 (en)	1996-10-08	1998-04-16	Fujisawa Pharmaceutical Co., Ltd.	Indole derivatives
US5874437A (en)	1996-11-01	1999-02-23	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998038168A1 (en)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
RS50118B (sr)	1997-04-25	2009-03-25	Pfizer Inc.,	Pirazolopirimidinoni koji inhibiraju tip 5 ciklične guanozin 3',5'-monofosfat fosfo-diesteraze (cgmp pde5) za tretman seksualne disfunkcije
US6027494A (en) *	1997-06-06	2000-02-22	Autonomous Technologies Corporation	Ablatement designed for dark adaptability
DE69826286T2 (de)	1997-06-27	2005-11-24	Fujisawa Pharmaceutical Co., Ltd.	Derivate mit einem aromatischen ring
TW453999B (en)	1997-06-27	2001-09-11	Fujisawa Pharmaceutical Co	Benzimidazole derivatives
JP2002509553A (ja)	1997-10-27	2002-03-26	藤沢薬品工業株式会社	ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物
US6403597B1 (en)	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037346A (en)	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2003525845A (ja)	1997-10-28	2003-09-02	ヴィヴァス・インコーポレイテッド	勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
WO1999021562A1 (en)	1997-10-28	1999-05-06	Asivi, Llc	Treatment of female sexual dysfunction
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
CA2309332C (en)	1997-11-12	2002-12-03	Bayer Aktiengesellschaft	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP1057819A4 (en)	1998-02-19	2003-02-05	Eisai Co Ltd	PHTALAZINE DERIVATIVES AND REMEDIES FOR DYSERECTION
AU2641099A (en)	1998-02-27	1999-09-15	Kyowa Hakko Kogyo Co. Ltd.	Imidazoquinazoline derivatives
AU2641199A (en)	1998-02-27	1999-09-15	Kyowa Hakko Kogyo Co. Ltd.	Remedies for erectile dysfunction
DE19816857A1 (de)	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL343794A1 (en)	1998-04-20	2001-09-10	Pfizer	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
WO1999062905A1 (en)	1998-06-03	1999-12-09	Almirall Prodesfarma, S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087362A (en)	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
US6023640A (en)	1999-03-29	2000-02-08	Ross; Jesse	Method contributing to obviating male impotency
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
SK286975B6 (sk) *	2001-02-24	2009-08-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
EP1463727A2 (en) *	2001-09-19	2004-10-06	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
ATE409466T1 (de) *	2002-01-11	2008-10-15	Novo Nordisk As	Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
MXPA04011862A (es) *	2002-05-31	2005-03-31	Schering Corp	Procedimiento para preparar inhibidores xantina de la fosfodiesterasa v, y precursores de los mismos.
WO2003101991A1 (en) *	2002-05-31	2003-12-11	Schering Corporation	Xanthine phosphodiesterase v inhibitor polymorphs
JP2007500714A (ja) *	2003-07-31	2007-01-18	シェーリング　コーポレイション	勃起不全を処置するのに有用なキサンチンホスホジエステラーゼ５インヒビターの代謝物およびそれらの誘導体

2001
- 2001-08-28 US US09/940,760 patent/US6821978B2/en not_active Expired - Fee Related
- 2001-09-17 NZ NZ524433A patent/NZ524433A/en not_active IP Right Cessation
- 2001-09-17 KR KR1020037003898A patent/KR100610417B1/ko not_active Expired - Fee Related
- 2001-09-17 SI SI200130934T patent/SI1319003T1/sl unknown
- 2001-09-17 WO PCT/US2001/028983 patent/WO2002024698A1/en not_active Ceased
- 2001-09-17 BR BR0113953-3A patent/BR0113953A/pt not_active Application Discontinuation
- 2001-09-17 IL IL15483901A patent/IL154839A0/xx unknown
- 2001-09-17 DE DE60138955T patent/DE60138955D1/de not_active Expired - Lifetime
- 2001-09-17 JP JP2002529108A patent/JP4015547B2/ja not_active Expired - Fee Related
- 2001-09-17 CN CNB018159125A patent/CN1252071C/zh not_active Expired - Fee Related
- 2001-09-17 ES ES01971092T patent/ES2326956T3/es not_active Expired - Lifetime
- 2001-09-17 AT AT01971092T patent/ATE433451T1/de active
- 2001-09-17 RU RU2003111460/04A patent/RU2302420C9/ru not_active IP Right Cessation
- 2001-09-17 HU HU0303016A patent/HUP0303016A3/hu unknown
- 2001-09-17 EP EP01971092A patent/EP1319003B1/en not_active Expired - Lifetime
- 2001-09-17 CA CA002421910A patent/CA2421910C/en not_active Expired - Fee Related
- 2001-09-17 AU AU2001291022A patent/AU2001291022B2/en not_active Ceased
- 2001-09-17 MX MXPA03002361A patent/MXPA03002361A/es active IP Right Grant
- 2001-09-17 AU AU9102201A patent/AU9102201A/xx active Pending
- 2001-09-17 PL PL361729A patent/PL205188B1/pl not_active IP Right Cessation
- 2001-09-17 DK DK01971092T patent/DK1319003T3/da active
- 2001-09-17 PT PT01971092T patent/PT1319003E/pt unknown
- 2001-09-17 SK SK319-2003A patent/SK3192003A3/sk unknown
- 2001-09-18 AR ARP010104405A patent/AR035199A1/es active IP Right Grant
- 2001-09-18 PE PE2001000936A patent/PE20020469A1/es not_active Application Discontinuation
- 2001-09-19 TW TW090123426A patent/TWI241301B/zh not_active IP Right Cessation
2003
- 2003-03-06 ZA ZA200301863A patent/ZA200301863B/en unknown
- 2003-03-18 NO NO20031238A patent/NO328753B1/no not_active IP Right Cessation
- 2003-03-19 EC EC2003004519A patent/ECSP034519A/es unknown
2004
- 2004-02-12 US US10/777,849 patent/US7268141B2/en not_active Expired - Fee Related
- 2004-06-09 US US10/864,218 patent/US20040229885A1/en not_active Abandoned
- 2004-11-16 US US10/990,083 patent/US20050075349A1/en not_active Abandoned
2005
- 2005-03-11 US US11/078,999 patent/US20050182077A1/en not_active Abandoned
2007
- 2007-08-02 JP JP2007202402A patent/JP2007297409A/ja not_active Withdrawn
- 2007-09-10 US US11/852,638 patent/US7531544B2/en not_active Expired - Fee Related
2009
- 2009-08-24 CY CY20091100890T patent/CY1109329T1/el unknown

Also Published As

Publication number	Publication date
PT1319003E (pt)	2009-07-23
IL154839A0 (en)	2003-10-31
AU9102201A (en)	2002-04-02
ATE433451T1 (de)	2009-06-15
KR100610417B1 (ko)	2006-08-08
DE60138955D1 (en)	2009-07-23
HK1056550A1 (en)	2004-02-20
US20040229885A1 (en)	2004-11-18
BR0113953A (pt)	2003-07-22
CY1109329T1 (el)	2014-07-02
NO20031238D0 (no)	2003-03-18
US20020169174A1 (en)	2002-11-14
MXPA03002361A (es)	2003-06-30
DK1319003T3 (da)	2009-09-28
KR20030036800A (ko)	2003-05-09
ECSP034519A (es)	2003-04-25
US7268141B2 (en)	2007-09-11
SI1319003T1 (sl)	2009-10-31
ES2326956T3 (es)	2009-10-22
NO328753B1 (no)	2010-05-03
RU2302420C2 (ru)	2007-07-10
NZ524433A (en)	2004-09-24
PL361729A1 (en)	2004-10-04
TWI241301B (en)	2005-10-11
EP1319003A1 (en)	2003-06-18
JP4015547B2 (ja)	2007-11-28
ZA200301863B (en)	2004-06-22
AR035199A1 (es)	2004-05-05
CA2421910C (en)	2007-07-10
JP2004509892A (ja)	2004-04-02
HUP0303016A2 (hu)	2003-12-29
PE20020469A1 (es)	2002-06-18
EP1319003B1 (en)	2009-06-10
HUP0303016A3 (en)	2007-03-28
US7531544B2 (en)	2009-05-12
US20050182077A1 (en)	2005-08-18
CA2421910A1 (en)	2002-03-28
CN1460105A (zh)	2003-12-03
US6821978B2 (en)	2004-11-23
US20050075349A1 (en)	2005-04-07
US20040167137A1 (en)	2004-08-26
WO2002024698A1 (en)	2002-03-28
PL205188B1 (pl)	2010-03-31
SK3192003A3 (en)	2003-08-05
US20080058354A1 (en)	2008-03-06
AU2001291022B2 (en)	2007-01-18
JP2007297409A (ja)	2007-11-15
CN1252071C (zh)	2006-04-19
RU2302420C9 (ru)	2008-12-10

Publication	Publication Date	Title
DK1319003T3 (da)	2009-09-28	Xanthin-phosphodiesterase V-inhibitorer
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
ATE278690T1 (de)	2004-10-15	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DK1268480T3 (da)	2004-03-15	8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
ATE395349T1 (de)	2008-05-15	Polycyclische guanin phosphodiesterase inhibitoren
ATE325807T1 (de)	2006-06-15	Purinderivate
DE60130463D1 (de)	2007-10-25	Pyrimidin-derivate
ATE267836T1 (de)	2004-06-15	Purinderivate
ATE318603T1 (de)	2006-03-15	Pyrrolotriazin kinasehemmer
MA25996A1 (fr)	2003-12-31	Inhibiteurs de phosphodiesterase 4.
DK1272488T3 (da)	2006-07-17	Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
NO20032291D0 (no)	2003-05-21	Pyrimidinderivater
EP1570847A4 (en)	2008-10-08	PHOSPHODIESTERASE 10A HEMMER
AR028075A1 (es)	2003-04-23	Inhibidores de la peptido-desformilasa
SI1296981T1 (en)	2005-02-28	Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IDP000027420A (id)	2001-12-20	Inhibitor-inhibitor kinase pirolotriazin

Legal Events

Date	Code	Title	Description
2013-04-22	MM1K	Lapsed by not paying the annual fees